

<b>Supplementary table.</b> List of clinical practice guidelines for the management of ovarian cancer			
Country	Organization	Included guideline(s)	Years published/ revised
Norway	Norwegian Directorate of Health (NDH)	Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up <sup>1</sup>	2016
Australia	Cancer Australia (CA)	Recommendations for the management of women at high risk of ovarian cancer <sup>2</sup> Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer <sup>3</sup> Optimal Care Pathway for Women with Ovarian Cancer <sup>4</sup>	2004, 2011 2004, 2014, 2016
Denmark	Danish Gynaecological Cancer Group (DGCG)	National Ovarian Cancer Guidelines <sup>5</sup>	2003, 2007, 2010, 2014 2017
Canada	Alberta Health Services	Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer <sup>6</sup>	2011, 2012, 2013
	British Columbia Cancer	Ovary – Epithelial Carcinoma <sup>7</sup>	2018
	Cancer Care Ontario (CCO)	The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer <sup>8</sup>	2006, 2012
		Management of a suspicious adnexal mass <sup>9</sup>	2011, 2016
		First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer <sup>10</sup> Organizational Guideline for Gynecologic Oncology Services in Ontario Systemic Therapy for Recurrent Epithelial Ovarian Cancer <sup>11</sup> Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map <sup>12</sup>	2001, 2004, 2012, 2013 2003, 2006, 2011, 2016, 2018
UK	National Institute for Health and Care Excellence (NICE)	Ovarian cancer: recognition and initial management <sup>13</sup>	2011
		Ultra-radical (extensive) surgery for advanced ovarian cancer <sup>14</sup>	2013
		Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer <sup>15</sup>	2013
		Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy <sup>16</sup>	2019
Scotland	British Gynaecological Cancer Society (BGCS)	Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice <sup>17</sup>	2017
	Scottish Intercollegiate Guidelines Network (SIGN)	Management of epithelial ovarian cancer <sup>18</sup>	2003, 2013, 2018
South Wales	South Wales Cancer Network (SWCN)	South Wales Gynaecology Clinical Guidelines <sup>19</sup>	2011
North Wales	North Wales Cancer Network (NWCN)	North Wales Ovarian Cancer Guidelines <sup>20</sup>	2015
Northern Ireland	Northern Ireland Cancer Network (NICaN)	Systematic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer <sup>21</sup>	2017
New Zealand	New Zealand Ministry of Health (NZMH)	Standards of Service Provision for Gynaecological Cancer Patients in New Zealand – <i>Provisional</i> <sup>22</sup>	2013
Ireland	National Cancer Control Programme (NCCP)	-	-
Other international guidelines	National Comprehensive Cancer Network (NCCN)	Epithelial Ovarian Cancer <sup>23</sup>	2019*
	American Society of Clinical Oncology (ASCO)	Neoadjuvant Chemotherapy for Ovarian Cancer <sup>24</sup>	2016
	European Society of Medical Oncology (ESMO)	Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines <sup>25</sup>	2013, 2016
		European Society of Gynaecological Oncology (ESGO)	Ovarian Cancer Surgery Guidelines <sup>26</sup>

\*Updated on a continuous basis, at least annually

**Additional references:**

- <sup>1</sup>Norwegian Directorate for Health (NDH). Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up. NDH National Professional Guidelines 2016. Available at: <https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-handlingsprogram>
- <sup>2</sup>National Breast and Ovarian Cancer Centre (NBOCC). Recommendations for the management of women at high risk of ovarian cancer. Cancer Australia 2011. Available at: [https://guidelines.canceraustralia.gov.au/guidelines/guideline\\_14.pdf](https://guidelines.canceraustralia.gov.au/guidelines/guideline_14.pdf)
- <sup>3</sup>Cancer Australia. Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer. Australian Government 2014. Available at: <https://canceraustralia.gov.au/publications-and-resources/clinical-practice-guidelines/first-line-chemotherapy-treatment-women-epithelial-ovarian-cancer>
- <sup>4</sup>Cancer Australia. Optimal Care Pathway for Women with Ovarian Cancer. Australian Government 2016. Available at: <https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-for-women-with-ovarian-cancer-june-2016.pdf>
- <sup>5</sup>Danish Gynaecological Cancer Group (DGCG). National Ovarian Cancer Guidelines: Recommendations for the management of all histological subtypes. DGCG 2018.
- <sup>6</sup>Alberta Health Services (AHS). Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. AHS 2013. Available at: <https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gyne005-epithelialovarian.pdf>
- <sup>7</sup>British Columbia (BC) Cancer. Ovary – Epithelial Carcinoma. BC Cancer 2018. Available at: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/gynecology/ovary-epithelial-carcinoma>
- <sup>8</sup>Members of the Gynecology Cancer Disease Site Group. The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer. Cancer Care Ontario (CCO) 2012.
- <sup>9</sup>Dodge J, Covens A, Lacchetti C, Elit L, Le T, Devries-Aboud M et al. Management of a suspicious adnexal mass. Cancer Care Ontario (CCO) 2016.
- <sup>10</sup>Members of the Gynecology Cancer Disease Site Group. First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Cancer Care Ontario (CCO) 2013.
- <sup>11</sup>Fung-Kee-Fung M, Kennedy E, Biagi J, Colgan T, D'Souza D, Elit L, Hunter A, et al. Organisational guideline for Gynecologic Oncology services. Cancer Care Ontario (CCO) 2013. Available at:
- <sup>12</sup>Cancer Care Ontario. Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map (version 2018.06). Available at: <https://www.cancercareontario.ca/sites/ccocancercare/files/assets/CCOOvarySerousTreatmentPathway.pdf>
- <sup>13</sup>National Institute of Health and Care Excellence NICE). Ovarian cancer: recognition and initial management. Clinical guideline [CG122]. 2011. Available at: <https://www.nice.org.uk/guidance/cg122>

- 
- <sup>14</sup> National Institute of Health and Care Excellence (NICE). Ultra-radical (extensive) surgery for advanced ovarian cancer. Interventional procedures guidance [IPG470] 2013. Available at: <https://www.nice.org.uk/guidance/IPG470>
- <sup>15</sup> National Institute of Health and Care Excellence (NICE). Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE 2013.
- <sup>16</sup> NICE. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598]. Published 28<sup>th</sup> August 2019. Available at: <https://www.nice.org.uk/guidance/ta598>
- <sup>17</sup> Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice. BGCS 2017
- <sup>18</sup> Scottish Intercollegiate Guidelines Network (SIGN). SIGN 135: Management of epithelial ovarian cancer. Health Improvement Scotland (HIS) 2013 [updated in 2018]
- <sup>19</sup> South Wales Cancer Network (SWCN). South Wales Gynaecology Clinical Guidelines. NHS Wales 2011.
- <sup>20</sup> North Wales Cancer Network (NWCN) North Wales Cancer Guidelines: Ovarian Cancer. NHS Wales 2015.
- <sup>21</sup> McKenna S and Miller J. Systematic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer. Northern Ireland Cancer Network (NICAN) 2017.
- <sup>22</sup> National Gynaecological Cancer Tumour Standards Working Group. Standards of Service Provision for Gynaecological Cancer Patients in New Zealand – Provisional. Wellington: Ministry of Health 2013.
- <sup>23</sup> National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer: including fallopian tube cancer and primary peritoneal cancer, version 2.2018. NCCN 2018.
- <sup>24</sup> Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RI, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline. *J Clin Oncol* 2016;34:3460-73.
- <sup>25</sup> Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2013;24(6):24–32.
- <sup>26</sup> Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. *Int J Gynecol Cancer* 2017.